A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA; Cancer Chemotherapy And Pharmacology, 2010, vol. 66, issue 6, p 1051, ISSN 14320843. ISBN 14320843.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef